The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Primary objective met in the DREAMM-2 trial of belantamab mafodotin in relapsed/refractory multiple myeloma
On 23rd August 2019, headline results from the pivotal DREAMM-2 open-label, two-arm, randomized, phase II study of belantamab mafodotin (NCT03525678) were released.1 Belantamab mafodotin is an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate and the DREAMM-2 trial investigated the safety and efficacy at two doses in 196 patients with relapsed or refractory (R/R) multiple myeloma (MM) who had received more than three prior treatments, failed an anti-CD38 antibody and were refractory to a proteasome inhibitor and an immunomodulatory drug.
DREAMM-2 met its primary endpoint demonstrating a clinically meaningful overall response rate (ORR) and the safety profile was consistent with that observed in the preceding phase I trial - DREAMM-1.1
The results from DREAMM-2 will form the basis of regulatory submission for belantamab mafodotin, which is expected by the end of 2019.
Currently there are ongoing studies which are investigating belantamab mafodotin as third-line monotherapy in R/R MM and as a combination therapy in first- and second-line treatment.
References